Lupin Limited shares are trading higher at RS. 1966.00, up by 20.90 points or 1.07% from the previous close of RS. 1945.10 on the BSE.

The stock opened at RS. 1959.35 and touched an intraday high of RS. 1966.00 and a low of RS. 1937.10. A total of 2201 shares have been traded so far.

In the BSE ‘A’ group, the company’s stock with a face value of RS. 2 has recorded a 52-week high of RS. 2403.45 on January 2, 2025, and a 52-week low of RS. 1774.00 on April 7, 2025. Over the past week, the scrip has traded between RS. 1972.80 and RS. 1900.30. The company’s current market capitalization stands at RS. 88,557.61 crore.

Promoter shareholding in the company is 46.90%, while institutional and non-institutional investors hold 47.06% and 6.06%, respectively.

In a major development, Lupin Digital Health, a wholly owned subsidiary of Lupin, has launched VITALYFE, an AI-driven cardiometabolic wellness platform aimed at helping India’s working professionals improve heart health. The platform builds on LYFE, India’s first CDSCO-approved Class C software medical device (SaMD) for critical cardiac conditions, extending hospital-grade expertise into preventive wellness.

VITALYFE integrates artificial intelligence, behavioral science, and computer-vision technology to identify early risks and offer personalized, non-medical interventions targeting the root causes of heart aging. Available exclusively through insurers, brokers, and employers, the platform enables organizations to incorporate cardiometabolic wellness into employee health programs—enhancing productivity, engagement, and well-being while helping insurers reduce lifestyle-related claims.

Lupin continues to strengthen its position as an innovation-led global pharmaceutical company, engaged in developing, manufacturing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide.